DK1150714T3 - Fremgangsmåder til inhibering af hjernetumorvækst - Google Patents

Fremgangsmåder til inhibering af hjernetumorvækst

Info

Publication number
DK1150714T3
DK1150714T3 DK00905742T DK00905742T DK1150714T3 DK 1150714 T3 DK1150714 T3 DK 1150714T3 DK 00905742 T DK00905742 T DK 00905742T DK 00905742 T DK00905742 T DK 00905742T DK 1150714 T3 DK1150714 T3 DK 1150714T3
Authority
DK
Denmark
Prior art keywords
brain tumor
tumor growth
methods
inhibiting brain
brain
Prior art date
Application number
DK00905742T
Other languages
English (en)
Inventor
Walter E Laug
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26815994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1150714(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Application granted granted Critical
Publication of DK1150714T3 publication Critical patent/DK1150714T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK00905742T 1999-02-01 2000-01-26 Fremgangsmåder til inhibering af hjernetumorvækst DK1150714T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11812699P 1999-02-01 1999-02-01
US09/489,391 US6521593B1 (en) 1999-02-01 2000-01-21 Methods for inhibiting brain tumor growth
PCT/US2000/001949 WO2000044404A2 (en) 1999-02-01 2000-01-26 Methods for inhibiting brain tumor growth by using selected integrin antagonists

Publications (1)

Publication Number Publication Date
DK1150714T3 true DK1150714T3 (da) 2008-08-18

Family

ID=26815994

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00905742T DK1150714T3 (da) 1999-02-01 2000-01-26 Fremgangsmåder til inhibering af hjernetumorvækst

Country Status (21)

Country Link
US (2) US6521593B1 (da)
EP (1) EP1150714B1 (da)
JP (1) JP4708568B2 (da)
KR (1) KR100704139B1 (da)
CN (2) CN1332713C (da)
AT (1) ATE395934T1 (da)
AU (2) AU775064B2 (da)
BR (1) BR0007875A (da)
CA (1) CA2360146C (da)
CZ (1) CZ301480B6 (da)
DE (1) DE60038951D1 (da)
DK (1) DK1150714T3 (da)
ES (1) ES2304942T3 (da)
HU (1) HU230025B1 (da)
MX (1) MXPA01007765A (da)
NO (1) NO329695B1 (da)
PL (1) PL202082B1 (da)
PT (1) PT1150714E (da)
RU (1) RU2377017C2 (da)
SK (1) SK287326B6 (da)
WO (1) WO2000044404A2 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040597A1 (en) * 1999-01-06 2000-07-13 University Of Southern California Method and composition for angiogenesis inhibition
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
EP1414491A4 (en) * 2001-07-09 2005-07-06 Elan Pharm Inc METHOD OF INHIBITING THE TOXICITY OF AMYLOID
US7829087B2 (en) 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
WO2005044978A2 (en) * 2003-07-15 2005-05-19 Washington University Methods of treating, preventing and inhibiting cancer metastasis and tumor formation
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
WO2005027895A2 (en) * 2003-09-15 2005-03-31 Ordway Research Institute Thyroid hormone analogs and methods of use in angiogenesis
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
ITRM20040105A1 (it) * 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
US20090035312A1 (en) * 2005-09-30 2009-02-05 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP2054442A2 (en) * 2006-06-14 2009-05-06 Cell-Matrix, Inc. Denatured collagen peptides and uses thereof
KR20090039739A (ko) 2006-08-03 2009-04-22 아스트라제네카 아베 αＶβ６에 대해 작용하는 항체 및 그의 용도
AU2007353426A1 (en) * 2006-12-22 2008-11-20 Albany College Of Pharmacy And Health Sciences Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
WO2009026681A1 (en) * 2007-08-24 2009-03-05 University Health Network Methods of inhibiting tumor growth using beta 5 integrin antagonists
ES2440565T3 (es) 2008-12-23 2014-01-29 Merck Patent Gmbh Biomarcadores para inhibidores con actividad anti-angiogénica
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
WO2010120506A1 (en) * 2009-03-31 2010-10-21 Ordway Research Institute, Inc. Combination treatment of cancer with cetuximab and tetrac
CN101659694B (zh) * 2009-05-06 2012-12-12 河北科技大学 抗肿瘤环五肽化合物及其制备方法
WO2010148007A2 (en) * 2009-06-17 2010-12-23 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
CN103209690A (zh) 2010-06-30 2013-07-17 盖尔德马研究及发展公司 α肾上腺素能受体激动剂用于预防或治疗皮肤肿瘤的用途
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
CN102145161A (zh) * 2011-04-07 2011-08-10 中国药科大学 整合素阻断剂在制备治疗肿瘤药物中的应用
JP6426001B2 (ja) 2011-11-17 2018-11-21 グリア エスピー ゼット．オー．オー． 神経膠腫を治療するための組成物および方法
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
US20170000905A1 (en) * 2015-06-30 2017-01-05 Mousera, Inc Device and method of personalized medicine
CN109715551A (zh) 2016-06-07 2019-05-03 纳米药业有限责任公司 与αvβ3整联蛋白甲状腺拮抗剂缀合的不可裂解聚合物
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
RU2709215C1 (ru) * 2019-09-12 2019-12-17 Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Институт катализа им. Г.К. Борескова Сибирского отделения Российской академии наук" (ИК СО РАН) Способ подавления роста опухолей глиального происхождения
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP0719859B1 (en) * 1994-12-20 2003-07-02 MERCK PATENT GmbH Anti-alpha V-integrin monoclonal antibody
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19613933A1 (de) * 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
ATE470450T1 (de) * 1996-05-31 2010-06-15 Scripps Research Inst Zusammenstellungen zur verwendung als alpha-v- beta3 vermittelter angiogenesis hemmers
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
CZ20002269A3 (cs) * 1998-12-14 2001-01-17 Merck & Co., Inc. Látky antagonizující receptor íntegrinu

Also Published As

Publication number Publication date
AU2004220756A1 (en) 2004-11-11
JP4708568B2 (ja) 2011-06-22
HUP0105155A3 (en) 2004-08-30
CN1332713C (zh) 2007-08-22
CA2360146A1 (en) 2000-08-03
RU2377017C2 (ru) 2009-12-27
US20030157098A1 (en) 2003-08-21
NO20013750D0 (no) 2001-07-31
EP1150714B1 (en) 2008-05-21
CN1191858C (zh) 2005-03-09
WO2000044404A2 (en) 2000-08-03
PT1150714E (pt) 2008-07-30
HUP0105155A2 (hu) 2002-04-29
NO329695B1 (no) 2010-12-06
JP2002535375A (ja) 2002-10-22
US6521593B1 (en) 2003-02-18
SK287326B6 (sk) 2010-07-07
KR100704139B1 (ko) 2007-04-09
PL202082B1 (pl) 2009-05-29
DE60038951D1 (de) 2008-07-03
KR20020001726A (ko) 2002-01-09
PL359602A1 (en) 2004-08-23
NO20013750L (no) 2001-09-28
CZ301480B6 (cs) 2010-03-17
RU2005107614A (ru) 2006-08-27
AU2004220756B2 (en) 2007-05-10
AU775064B2 (en) 2004-07-15
CZ20012793A3 (cs) 2002-03-13
HU230025B1 (hu) 2015-05-28
WO2000044404A3 (en) 2000-11-30
ES2304942T3 (es) 2008-11-01
EP1150714A2 (en) 2001-11-07
BR0007875A (pt) 2002-02-13
AU2737900A (en) 2000-08-18
ATE395934T1 (de) 2008-06-15
CN1355711A (zh) 2002-06-26
CN1660426A (zh) 2005-08-31
CA2360146C (en) 2013-05-21
SK10622001A3 (sk) 2002-04-04
MXPA01007765A (es) 2003-06-04

Similar Documents

Publication Publication Date Title
DK1150714T3 (da) Fremgangsmåder til inhibering af hjernetumorvækst
AU4721901A (en) Integrin antagonists
DE69928697D1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
DE60044004D1 (de) Verwendung von Omega-Carboxyaryl-substituierten Diphenylharnstoffen als raf-Kinase-Inhibitoren
BRPI0412993A (pt) inibidores da atividade da akt
DE69939168D1 (de) Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
IS2631B (is) Aðferðir þar sem integrín-mótlyf eru notuð til að meðhöndla margföld mergæxli og uppsog í bein af völdum mergæxla
DK1218494T3 (da) Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler
HK1071697A1 (en) Inhibition of the growth factor dependency of tumor cells
GB2393735B (en) Cell culture method for obtaining prostate-like acini
ATE250074T1 (de) 2,3-o-isoproylidene derivativen von monosacchariden und verwendung als zell-adhäsion- inhibitoren
DE1206274T1 (de) Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung
YU30003A (sh) Inhibicija zavisnosti faktora rasta na ćelije tumora
EP1196449A4 (en) METHOD FOR MODULATING INTEGRIN-MEDIATED CELL ACTIVITY AND REAGENTS SUITABLE FOR THIS
DE60011801D1 (de) Benzoxa- und benzthiazolylsulfamate sowie ihre verwendung als steroid-sulfataseinhibitoren
BR9811470A (pt) Derivados de benzo (5,6) ciclohepta (1,2-b) piridina para a inibição da transferase da proteìna farnesil.
WO2006124626A3 (en) Inhibition of the 44 kilodalton isoform of pim-1 kinase restores apoptosis induced by chemotherapeutic drugs in cancer cells
ZA200110213B (en) The use of the protein UK 114 for inhibiting organ transplant rejection.
DE69901819T2 (de) Neue kristallkomplexe von baccatin iii mit imidazol, 2-methylimidazol or isopropanol